Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Harmony Gold Mining Co. (HMY) Price & Performance

Cytokinetics IncTrade
Harmony Gold Mining Co.Trade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Harmony Gold Mining Co. — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Harmony Gold Mining Co. trades at $19.48 (market cap $12.24B). The key difference: Harmony Gold Mining Co. is the larger of the two by market cap, and Harmony Gold Mining Co. pays a 2.09% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKHMY
Market Cap
$10.63B$12.24B
Sector
TechnologyBasic Materials
52-Week High
$87.26$26.04
52-Week Low
$34.31$12.61
Enterprise Value
$10.74B$12.58B
Dividend Yield
2.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.

The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.

Harmony Gold Mining Co.

Harmony Gold Mining (HMY) trades at $19.88, down 0.1% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, supported by a strategic pivot to gold-copper production. Recent news highlights operational progress, including copper profit growth and diversification efforts.

HMY offers value with a P/E of 12.26 and robust profitability margins, but faces risks from gold price volatility and mixed analyst sentiment. The stock's outlook is supported by earnings growth and diversification, though investor caution is warranted due to Fed policy sensitivity and execution risks in expansion.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Harmony Gold Mining Co.

Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.

Read more on HMY